B Introduction: b The generic rebranding of vasopressin resulted in an increase in medication costs requiring many healthcare systems to consider cost-savings strategies. B Conclusion: b Changing the vasopressin formulation to eliminate waste during compounding and removing it from ADCs to avoid duplicate compounding resulted in a significant cost-savings to the health system. The primary outcome is the estimated annual cost savings due to a formulation change with a secondary outcome as estimated annual cost savings due to removal from the ADC. [Extracted from the article]